Ask AI
Selecting Patients for Bridging Therapy in RR MM

CE / CME

Identifying Patients Likely to Benefit From Bridging Therapy Before CAR T-Cell Infusion  in R/R MM 

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 29, 2025

Expiration: June 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2025;43:2766-2771.
  2. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2025;43(suppl 1):4-9.
  3. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  4. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002-1014.
  5. Einsele H, Rodriguez-Otero P, Arnulf B, et al. Idecabtagene vicleucel (ide-cel) versus standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: KarMMa-3 subgroup analysis in patients receiving bridging therapy. Presented at: International Myeloma Society (IMS) 2023 Annual Meeting; September 37-30, 2023. Poster P-008.
  6. Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. Blood Cancer Discov. 2025;6:38-54.
  7. Idecabtagene vicleucel [prescribing information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2025.
  8. Ciltacabtagene autoleucel [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2025.
  9. Hwa YL, Doss D, Mangan PA, et al. Understanding the role and clinical management of bridging therapy during CAR T-cell therapy for relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2025;[Epub ahead of print].
  10. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41:8009.
  11. Ailawadhi S, Anderson LD Jr, Dhakal B, et al. Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2025;[Epub ahead of print].
  12. Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.
  13. Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56:552-566.
  14. Sidana S, Reid B, Dima D, et al. Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality. Presented at: 2025 American Society of Hematology annual meeting; December 6-9, 2025. Abstract 1034.
  15. Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29:440-448.
  16. Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025;146:2063-2072.
  17. Cheng J, Song Y. Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: a meta-analysis. Biomol Biomed. 2025;25:2416-2427.
  18. Gantana EJ, Musekwa E, Chapanduka ZC. Advances in estimating plasma cells in bone marrow: a comprehensive method review. Afr J Lab Med. 2024;13:2381.